Homepage Top Section2

The funding coincides with the in-licensing of SLTE-1009, an anti-PACAP monoclonal antibody acquired from DartsBio Pharmaceuticals (Guangdong). The company is headed by CEO and board director Gregory Oakes,

This marks a key development in the potential approval of adrabetadex, which could become a disease-modifying treatment for this rare paediatric neurodegenerative disorder. The FDA set 17 August

The submission targets adult patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated locally advanced or metastatic breast cancer that has progressed after previous endocrine-based

The MoU with the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli, including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), was signed at the

The partnership combines UNP’s AI-driven macrocycle platform with the worldwide development and commercialisation expertise of Novartis, aiming to produce next-generation treatments for previously undruggable targets. Under this agreement,

This combination, used alongside Lazcluze (lazertinib), is indicated as a first-line treatment for NSCLC. The therapy dosing provides clinical outcomes consistent with those of the earlier approved bi-weekly

This follows growing clinical evidence for Zemcelpro and interest from 220 hospitals in the country for potential use through the NUB mechanism from 2026. The European Commission (EC)

The submission sought accelerated approval and was part of the FDA Commissioner’s National Priority Voucher pilot programme. The CRL for bitopertin EPP affects the regulatory pathway and potential

The move is part of Ampersand’s strategy to establish a trans-Atlantic pharmaceutical development partnership through the Purna and MedPharm alliance. This partnership has the potential to become a